Phthalimide analogs of CB 1954: Synthesis and bioactivation

Anti-Cancer Drugs

Volumn 10, Issue 8, 1999, Pages 777-783

  Mehta, Lina K ^e   Hobbs, Steve ^a   Chen, Shuian ^b   Knox, Richard J ^c   Parrick, John ^d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Enzacta Ltd   (United Kingdom)

^d BRUNEL UNIVERSITY   (United Kingdom)

^e NONE

Author keywords

4 Substituted 5 nitrophthalimides; Bioreductive activation; DT diaphorase; Escherichia coli nitroreductase; Prodrug activation; Synthesis

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL CELL; ARTICLE; CELL STRAIN V 79; DRUG CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 0033384821     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199909000-00011     Document Type: Article

References (20)

1. 1. Khan AH, Ross WCJ. Tumor-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relation. Chem-Biol Interact 1969; 1: 27-47.
2. 2. Knox RJ, Friedlos F, Jarman M, Roberts JJ. A new cytotoxic, DNA interstrand crosslinking agent, 5-[aziridin-l-yl]-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 1988; 37: 4661-9.
3. 3. Boland MP, Knox RJ, Roberts JJ. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-[aziridin-l-yl]-2,4-dinitrobenzamide). Biochem Pharmacol 1991; 41: 867-75.
4. 4. Anlezark GM, Melton RG, Sherwood RF, et al. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol 1995; 50: 609-18.
5. 5. Bailey SM, Knox RJ, Hobbs SM, et al. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy, Gene Therapy 1996; 3: 1143-50.
6. 6. Chen S, Knox RJ, Lewis AD, et al. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes. Mol Pharmacol 1995; 47: 934-9.
7. 7. Bhat AV, Kesava Rao KV, Bapat CV. Response of human tumours 'in vitro' to CB 1954 (5-aziridinyl-2,4-dinitrobenzamide). Indian J Cancer 1977; 14: 132-5.
8. 8. Workman P, Morgan JE, Talbot K, Wright KA, Donaldson J, Twentyman PR. CB 1954 revisited II. Toxicity and antitumour activity. Cancer Chemother Pharmacol 1986; 16. 9-14.
9. 9. Riley RJ, Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 1992; 43: 1657-69.
10. 10. Chen S, Knox RJ, Wu K, et al. Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse. J Biol Chem 1997; 272: 1437-9.
11. 11. Bridgewater JA, Springer CJ, Knox RJ, et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrugs CB 1954. Eur J Cancer 1995; 31A: 2362-70.
12. 12. McNeish IA, Green NK, Gilligan MG, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Therapy 1998; 5: 1061-9.
13. 13. Cornish EJ, Lee GE, Wragg WR. The diuretic activity of clorexolone and some related phthalimides and 1-oxoisoindolines. J Pharm Pharmacol 1966; 18: 65-80.
14. 14. Levy LF, Stephen H. The preparation of 4-nitrophthalimide and derivatives, J Chem Soc 1931; 79-82.
15. 15. Billman JH, Cash RV. 4-Nitrophthalimides. I. Derivatives of alkyl halides giving a saponification equivalent. J Am Chem Soc 1953; 75: 2499-501.
16. 16. Tirouflet J, Dabard R. Synthesis of N-alkylphthalimides substituted in the aromatic ring. Compte Rendue 1956; 242: 916-8.
17. 17. Palmer BD, Wilson WR, Cliffe S, Denny WA. Hypoxia-selective antitumour agents. 5. Synthesis of water-soluble nitroaniline chloromustards and determination of their selective cytotoxicity for hypoxic mammalian cells. J Med Chem 1992; 35: 3214-22.
18. 18. Knox RJ, Friedlos F, Bolland MP. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metast Rev 1993; 12: 195-212.
19. 19. Friedlos F, Quinn J, Knox RJ, Roberts JJ. The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink. Biochem Pharmacol 1992; 43: 1249-54.
20. 20. Knox RJ, Friedlos F, Marchbank T, Roberts JJ, Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem Pharmacol 1991; 42: 1691-7.